In Vitro Study Demonstrates SIRT6 Activation by Hydrolyzed Yeast Protein Extract Mitigates Skin Aging Hallmarks
LONGEFI Signal
How this development was scored.
How authoritative and verifiable the underlying source is.
How prominent or noteworthy the development is based on its editorial classification.
How close this type of development sits to meaningful human clinical impact.
How strongly the development connects to companies and commercial or strategic context.
Measures significance, not direction or investment attractiveness.Methodology
A high LONGEFI Signal means the development is significant — not that it is positive news, a good investment, or expected to increase a company's share price.
Significance only. Direction-neutral: negative developments can score just as high. Not an investment rating, not a forecast, not a recommendation.
Event tier C · Tier ceiling 74 · LONGIFI_SIGNAL_V1
Quick take
An in vitro study demonstrated that a proprietary Hydrolyzed Yeast Protein Extract acts as a SIRT6 activator in human skin cells, reducing cellular hallmarks of aging such as DNA damage and telomere attrition to support its potential integration into topical anti-aging formulations.
What happened
Researchers evaluated a proprietary Hydrolyzed Yeast Protein Extract (HYPE) across normal human epidermal keratinocytes (NHEK), dermal fibroblasts, and a 3D skin model.
Treatment with HYPE increased SIRT6 protein expression in NHEK and gene expression in dermal fibroblasts.
HYPE exposure protected keratinocytes from UVB-induced DNA damage and attenuated NF-κB-mediated inflammatory responses.
The extract decreased the rate of telomere attrition in aged dermal fibroblasts and reduced melanin content in melanocytes in a 3D skin model.
Why it matters
SIRT6 plays a critical role in DNA repair and telomere maintenance, making its activation a significant target for cellular rejuvenation and senescence delay.
Demonstrating biological activity across keratinocytes, fibroblasts, and melanocytes suggests that HYPE can address multiple distinct cellular pathways of chronological and photo-induced skin aging.
Market impact
The translation of geroscience-derived mechanisms such as SIRT6 activation into topical ingredients highlights a growing commercial pathway for cosmetic and wellness brands.
Developing proprietary botanical or yeast-derived extracts provides a faster, non-clinical regulatory route to commercializing longevity-focused products compared to systemic therapeutic modalities.
What comes next
The potential formulation of commercial topical products containing Hydrolyzed Yeast Protein Extract and clinical studies evaluating their safety and efficacy in human subjects.
Company relevance
Structured relationships recorded at publication time. Sector exposure is thematic only — it does not mean the company took part. Not market data.
- Genflow Biosciences
Sector exposure · MECHANISM
Genflow Biosciences has historically worked on targeting SIRT6 through gene therapy, holding a preclinical program (GF-1002) for SIRT6-related age-related diseases. This preclinical research aligns with the study's focus on SIRT6 activation to address hallmarks of aging, though through a different therapeutic modality. (LONGEFI analysis)
Sources
- NCBIPUBMED:LONGEVITY_RESEARCH